Cancer Immunotherapy: Drugs, Predictive Markers, Successes and Failures
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Pharmacogenetics".
Deadline for manuscript submissions: closed (15 September 2020) | Viewed by 244
Special Issue Editor
Special Issue Information
Dear Colleagues,
The immunotherapy of cancer has advanced tremendously in the last decade, transforming the standard of care for many cancer types. This Issue aims to provide reviews of approved and investigational immune drugs in different categories: immune checkpoint drugs, adoptive cell transfer, immune cytokines, drugs activating the innate immune system and combinations thereof, or combinations with chemotherapy or targeted drugs. Some drugs in each category already have a proven track record in cancer treatment, while others are lagging behind for various reasons. The problems slowing down the progress could be ascribed to the lack of predictive markers of response to immune interventions; the relative prevalence of immune-cold cancers in general; and lack of a strong scientific rationale for the design of trials with drug combinations.
Dr. Emma Shtivelman
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immune checkpoint drugs
- adoptive T-cell transfer—heme cancers
- adoptive T-cell transfer—solid tumors
- TLR and STING agonists
- combination treatments with immune checkpoint drugs
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
